A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective...

Area of Science:

• Oncology
• Translational Cancer Research
• Preclinical Cancer Models

Background:

• Leiomyosarcoma is a rare and challenging cancer.
• Current first-line treatments like doxorubicin are often ineffective.
• Personalized cancer therapy requires accurate predictive models.

Purpose of the Study:

• To evaluate the efficacy of various chemotherapeutic agents in a patient-derived orthotopic xenograft (PDOX) model of leiomyosarcoma.
• To determine if the PDOX model can predict treatment response for leiomyosarcoma.

Main Methods:

• A recurrent leiomyosarcoma tumor was implanted into the femoral muscle of nude mice to create a PDOX model.
• The model was treated with doxorubicin, gemcitabine/docetaxel, trabectedin, temozolomide, pazopanib, and olaratumab.
• Treatment efficacy was assessed based on tumor response within the PDOX model.

Main Results:

• Gemcitabine/docetaxel, trabectedin, and temozolomide demonstrated high efficacy in the leiomyosarcoma PDOX model.
• Doxorubicin, pazopanib, and olaratumab were ineffective in this model.
• The PDOX model successfully differentiated between effective and ineffective treatments.

Conclusions:

• The patient-derived orthotopic xenograft model is a valuable tool for predicting treatment efficacy in leiomyosarcoma.
• This model can aid in individualizing therapy for patients with rare and recalcitrant leiomyosarcoma.
• Effective agents identified include gemcitabine/docetaxel, trabectedin, and temozolomide.